Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis. (2019)
Attributed to:
Wellcome Trust MRC Cambridge Stem Cell Institute
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.17863/cam.39579
Publication URI: https://www.repository.cam.ac.uk/handle/1810/292422
Type: Journal Article/Review